Series C+

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

With a $70M Series C and unique 3D printing tech, SWISSto12 proves the new space economy is moving beyond hype to sustainable, profitable infrastructure.

Emergent's massive Series C and unicorn status signal a new frontier for SMBs. But can its "agentic AI" truly deliver production-ready software, or do hidden costs and technical risks remain?

With a fresh $46M Series C, Quadric's programmable chips aim to free emerging markets from hyperscaler costs, fueling a new wave of on-device intelligence.

Liquid Instruments' GenInst Studio uses AI to build custom test gear from text prompts, slashing R&D time from months to minutes and challenging industry giants.

With new leaders from Coinbase and Adyen, Cardless is leveraging its $60M war chest to move beyond credit and build an AI-powered 'financial OS' for any brand.

With €33M in fresh capital, Cyllene Therapeutics is advancing a novel gene therapy for bladder disease. We analyze the tech, the investors, and the plan.

With a $76M Series C led by SBI Holdings, EDX Markets is scaling its institutional-grade crypto infrastructure, aiming to merge Wall Street's rigor with digital innovation.

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Eckuity Capital launches Fund II, leading a Series C in Automata Technologies with Danaher, signaling a major push to commercialize AI in life science labs.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Goldman Sachs leads a major investment in Taktile, betting that specialized 'Agentic AI' is the key to unlocking real value in the regulated financial sector.

Taktile secures a massive Goldman Sachs-led investment to embed AI agents in banking's core. Is this the tipping point for autonomous financial decisions?

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

The dream of the online side-hustle is burning out Australia's solo entrepreneurs. Can a new wave of AI assistants and a 'no app tax' model restore balance?

After conquering football, Scorability is expanding to seven new sports, leveraging AI and "mentality assessments" to change how colleges find talent.

A breakthrough 'pap smear for the pancreas' that detects early cancer has secured major funding, offering new hope against one of the deadliest diseases.

With a new $75M, Boston Metal scales its MOE tech to produce clean, critical metals from waste, aiming to secure supply chains and decarbonize industry.

This wearable combines Far Infrared tech and app control for under $200. But can a device born from an athlete's injury disrupt the recovery industry?